Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Date:11/7/2013

  • Year-end cash, cash equivalents and short-term investments are expected to be in the range of $25 - $35 million.
  • Based on its current expectations, the Company believes its capital resources as of September 30, 2013 will be sufficient to fund its currently planned operations into 2015 and through the expected release of final survival results from both the Synergy and Borealis-1 trials. The cash burn is expected to be reduced in 2014 compared with 2013 because the company-sponsored Borealis-1 trial is expected to incur the majority of its costs in 2013.  Further, the investigator-sponsored OGX-427 Phase 2 trials are substantially less capital-intensive than company-sponsored trials. 
  • At November 7, 2013, The Company had 14,707,636 shares outstanding.
  •  Consolidated Statements of Loss(In thousands, except per share and share data)(unaudited)Three months ended September 30,Nine months ended September 30,2013201220132012Collaboration revenue$
    9,862$
    ,570$
    21,278$
    ,315Operating expenses:  Research and development18,00412,89542,12224,303  General and administrative2,4731,9657,4465,749Total operating expenses20,47714,86049,56830,052Loss from operations(10,615)(8,290)(28,290)(19,737)  Other income5612,3703,1192,742Net loss$
    (10,054)$
    (5,920)$
    (25,171)$
    (16,995)Basic and diluted net loss per share$
    (0.68)$
    (0.40)$
    (1.72)$
    (1.29)Weighted average number of basic and diluted common shares14,690,98414,619,84214,675,24413,141,940Consolidated Balance Sheets(In thousands) September 30,  December 31, 20132012 (unaudited) Assets:  Cash, cash equivalents, short term investments and restricted cash$
    47,091$
    75,697  Interest receivable295327  Amounts receivable9,922714  Prepaid expenses and other current assets2,7133,755  Property, equipment and other assets1,6181,523Total assets$
    ,639$
    82,016Liabilities and stockholder
    '/>"/>

    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
    3. OncoGenex to Present at Credit Suisse Healthcare Investor Conference
    4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    6. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    7. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    8. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    10. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... 28, 2014  Next month, executives from clinical trial marketing ... events beginning with Patient-Centered Clinical Trials 2014 , to ... Boston , September 4-5. Patient recruitment experts Bonnie ... Fleishman will share insights on the benefits of employing ... tactics – from media to mobile apps – can be ...
    (Date:8/28/2014)... Sterlitech is proud to announce that ... stable of products . These additional products ... include membrane filters with surface charges. , ... for our membrane process testing equipment, and correspondingly, a ... membranes,” explains Sterlitech President Mark Spatz. “The addition ...
    (Date:8/28/2014)... Exciting new work by a Florida State University research ... can take your temperature, emit white light, and convert ... molecule looks like a butterfly. , Biwu Ma, associate ... in the FAMU-FSU College of Engineering, created the molecule ... continued to discover that his creation has many other ...
    (Date:8/28/2014)... Vt. (PRWEB) August 28, 2014 ... testing around the world is available from Strategic ... diagnostics companies. “ Industrial Microbiology Market Review, Fourth ... Industrial Market ” (IMMR—4) tracks and compares microbiology ... in North America, Europe and Asia, and forecasts ...
    Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3
    ... 29 Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ... and commercializing proprietary product candidates principally,for use ... the company,s,President and CEO Theodore Schroeder will ... 6 at 1:30pm Eastern Time (10:30am Pacific ...
    ... U.S. Attorney,s, Office for Eastern District of Pennsylvania and ... Settles State Cases with Connecticut and ... (Nasdaq:,CEPH) announced today it has finalized a previously announced ... Eastern District of,Pennsylvania, the U.S. Department of Justice and ...
    ... Calif., Sept. 29 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ... Jerry McMahon, Ph.D., chairman and CEO,will present at the ... 9 a.m. Eastern Time at Le Parker Meridien in ... overview, including a discussion,of the development of picoplatin, the ...
    Cached Biology Technology:Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference 2Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 2Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 3Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 4Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference 2
    (Date:9/1/2014)... 1, 2014, 10:20 AM EDT) It may be ... foods over unhealthy higher-calorie foods, according to new research ... Research Center on Aging (USDA HNRCA) at Tufts University ... the journal Nutrition & Diabetes , a brain ... it is possible to reverse the addictive power of ...
    (Date:9/1/2014)... ago, electron microscopy revealed the presence of tiny blob-like ... But scientists still don,t know what they do ... believed to be crucial to the life of a ... disease treatment., In the Journal of Cell Biology ... from various backgrounds, from biophysics to cell biology, to ...
    (Date:9/1/2014)... Section of the XVIII International Botanical Congress took place ... held every six years and it is where the ... fungi and plants get together to debate and update ... This is the primary product of the meeting, the ... which was published in 2012. The other important product ...
    Breaking Biology News(10 mins):Training your brain to prefer healthy foods 2Scientists call for investigation of mysterious cloud-like collections in cells 2Week-long meeting on naming algae, fungi, and plants recorded for posterity 2
    ... Works to Strengthen Security for Anyone with ... Sept. 17 Today a,Southwest Airlines pilot ... be screened by,the Transportation Security Administration (TSA) ... demonstration project called,SecureScreen will utilize biometrics to ...
    ... $24 million in federal funding to establish the University ... CEIN), which will help researchers design safer and more ... to be housed at the California NanoSystems Institute (CNSI) ... nanomaterials on life forms and the interactions of these ...
    ... Foundation (NSF) and the Environmental Protection Agency (EPA) have ... Implications of NanoTechnology (CEINT) to explore the potential ecological ... as a million times smaller than the head of ... objects made from the same material. These unusual properties ...
    Cached Biology News:Southwest Pilots Launch TSA Demonstration Project to Test Biometric Screening 2UCLA, partners establish new center on environmental effects of nanotechnology 2UCLA, partners establish new center on environmental effects of nanotechnology 3UCLA, partners establish new center on environmental effects of nanotechnology 4Duke to lead new NSF, EPA center to study the environmental implications of nanotechnology 2Duke to lead new NSF, EPA center to study the environmental implications of nanotechnology 3
    ... IT siRNA Tracker Intracellular Localization Kit provides ... and deliver siRNA, of your design, in ... vitro tracking experiments. Subcellular localization and functional ... monitored following introduction of the labeled siRNA ...
    ... Beacon 2000 instrument can be used as ... 2000 Data Manager Software provides the means ... from the instrument. These data can then ... spreadsheets, such as Microsoft Excel or Lotus ...
    ... for the study of protein:protein interactions from ... that interact with GST•Tag™, S•Tag™, or ... using affinity resins for the tags, and ... filter. The complexes are eluted with sample ...
    ... Microarray Kit (V2), 22K is useful for investigating ... Each microarray contains content derived from the ATH1 ... Research (TIGR) and represents 21,500 genes. ... x 3? glass slides each containing an identical ...
    Biology Products: